ClinicalTrials.gg
CompletedNCT03668028Updated May 18, 2023

A Phase I/III Clinical Study of TPX-114 for the Treatment of Full-Thickness Rotator Cuff Tear

A Phase 3 interventional study of TPX-114 and Arthroscopic surgery in Rotator Cuff Injuries, sponsored by Tego Science, Inc.. Completed at 2 sites in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2023-05-18.

Sponsored by Tego Science, Inc. · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
93
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Rotator Cuff Injuries with a site in Korea, Republic of — 3 open to participants now, 4 under way, 1 of them phase 3. Rotator Cuff Injuries · Korea, Republic of.

Enrollment
8th of 25
93 · median 74
Started
2018
with 1 other
Phase 3
2 of 30
none open now
Registered
13th of 30
by date
Lead sponsor
3 of 30
Tego Science, Inc.

Among the 30 studies in Rotator Cuff Injuries with a site in Korea, Republic of, this one is the 8th largest by enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2018, is one of 2 in phase 3, and was the 13th registered.

Rotator Cuff Injuries

632 studies on the registry are indexed under Rotator Cuff Injuries; 157 are open to participants now.

Browse Rotator Cuff Injuries studies →

Open to participants now

3 of the 30 studies in Rotator Cuff Injuries with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 100 Rotator Cuff Injuries studies recruiting now, 40 (40%) set no upper age limit and 41 (41%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Rotator Cuff Injuries with a site in Korea, Republic of, or all of them as a file.
02

Study summary

Rotator cuff tear is one of the most common shoulder diseases and retears occur frequently after arthroscopic repair. Therefore, there is a growing need of new therapy to improve structural outcome. This study evaluates the efficacy and safety of autologous fibroblasts during arthroscopic repair. The primary outcome is the retear rate at 24 weeks after administration of autologous fibroblasts (TPX-114) during arthroscopic repair. Secondary outcomes are functional evaluations including Range of Motion (ROM), Constant Score (CS), American Shoulder and Elbow Surgeons (ASES) score and Simple Shoulder Test (SST) at 24 and 52 weeks after administration.

03

Conditions studied

  • Rotator Cuff Injuries

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must;

  1. Be 19 years of age or older.
  2. Require arthroscopic repair for full-thickness rotator cuff tear(>2cm, ≤5cm) assessed by MRI without improvement of symptoms despite more than 3 months of conservative management.
  3. Consent to undergo skin to manufacture test product.
  4. Understand fully the study and voluntarily sign the for participation in the study.

Exclusion criteria

Exclusion Criteria:

Participants with any of the following conditions will be excluded unless stated otherwise;

  1. Unsuitable for skin .
  2. Have additional subscapularis tear.
  3. Have prior medical history of the following at the time of screening.

    • Operation of the affected shoulder
    • Allergies to bovine proteins
    • Anaphylaxis to gentamicin
    • Coagulopathy
    • Genetic disorders affecting fibroblasts or collagen (ex. achondroplasia, osteogenesis imperfecta)
    • Malignant tumors within the last 5 years
  4. Have been diagnosed with any of the following diseases at the time of screening.

    • disease (including RA)
    • Ab-positive
    • Acute trauma, chronic shoulder dislocation, pyogenic infection on the affected shoulder
    • Scapulohumeral osteoarthritis
  5. Be pregnant, breastfeeding, planning pregnancy or unwilling to use of suggested in this study.
  6. Other surgical or nonsurgical procedures on the affected shoulder to be judged more appropriate than arthroscopic repair.
  7. Have participated in and received agents in other clinical trials within 4 weeks of this study.
  8. Be deemed inadequate for the study by investigators.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
93 participants (actual)

Study arms

  • Experimental
    TPX-114

    Subjects undergo arthroscopic rotator cuff repair with TPX-114.

    Biological: TPX-114 · Procedure: Arthroscopic surgery

  • Placebo comparator
    Placebo

    Subjects undergo arthroscopic surgery for rotator cuff repair without TPX-114.

    Procedure: Arthroscopic surgery

Interventions

  • BiologicalTPX-114

    Subjects will be treated with autologous fibroblasts (TPX-114) during arthroscopic surgery.

  • ProcedureArthroscopic surgery

    Subjects undergo conventional arthroscopic surgery for rotator cuff repair.

06

What researchers measure

Primary outcomes

  1. Retear Rate

    Retear rate assessed by an independent evaluator with MRI

    Time frame: 24 weeks

07

Study locations

2 sites
  • Seoul National University Bundang Hospital
    Seongnam-si, Gyeonggi-do 13620, Korea, Republic of
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2018 to primary completion in Sep 2021, 38 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2018
First posted
Sep 12, 2018
StartActual
Jul 9, 2018
Primary completionActual
Sep 27, 2021
CompletionActual
Apr 28, 2022
Last update
May 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03668028
Lead sponsor
Tego Science, Inc.
Responsible party
Sponsor
First posted
Sep 12, 2018
Start date
Jul 9, 2018
Primary completion
Sep 27, 2021
Completion
Apr 28, 2022
Last update
May 18, 2023

Study contacts

Joo Han Oh
principal investigator · Seoul National University Bundang Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion